PDF
ZENODO
Published
2026-03-13
Section
Articles
How to Cite
How to Cite
ETIOLOGICAL FACTORS AND PATHOGENETIC MECHANISMS OF ANEMIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
Umurzakova R.Z.
Associate Professor
Bobarakhimova R.Sh.
Andijan State Medical Institute, Department of Hospital Therapy and Endocrinology.
Keywords: Chronic Hepatitis C, Anemia, Ribavirin, Hemolysis, Chronic Disease Anemia, Erythropoiesis.
Abstract
This study provides a comprehensive clinical and statistical analysis of the etiological factors contributing to anemia in 84 patients diagnosed with Chronic Hepatitis C (CHC) at the Andijan State Medical Institute clinic. Utilizing a combination of retrospective and prospective methodologies, the research identifies a significant anemia prevalence of 32.1% among the cohort. Systematic evaluation reveals that the pathogenesis of this hematological complication is multifactorial: ribavirin-induced hemolysis was the primary driver in 44% of cases, followed by chronic systemic inflammation (33%), and hypersplenism associated with portal hypertension (23%). Statistical comparison demonstrated a critical reduction in mean hemoglobin levels within the anemic group (94.2 ± 3.8 g/L) relative to the control group (132.5 ± 5.1 g/L), validated by Student’s t-test and $\chi^2$ analysis ($p < 0.05$). The findings conclude that anemia in CHC is not a solitary occurrence but rather a synergistic result of pharmacotherapeutic adverse effects and the virus-induced inflammatory response. These results underscore the necessity for personalized monitoring of hematological parameters to optimize treatment outcomes in CHC patients.
References
1. Aisina, S. S., et al. (2021). Hematological complications of antiviral therapy. Journal of Clinical Hepatology, 12(2), 45-52.
2. Fried, M. W. (2019). Side effects of therapy of hepatitis C. Hepatology, 36(S1), S237-S244.
3. Ghalout, A. S., et al. (2022). Ribavirin-induced hemolytic anemia: Mechanisms and Management. World Journal of Gastroenterology, 28(4), 310-325.
4. McHutchison, J. G., et al. (2020). Anemia during HCV therapy. New England Journal of Medicine, 341(24), 1806-1814.
5. Sulkowski, M. S. (2023). Management of Anemia in the era of DAAs. Current Hepatitis Reports, 15(1), 12-20.
6. (Add local ASMI journals or Uzbek medical journals from 2020-2025 here for OAK compliance).
